At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia in Low or Intermediate I Myelodysplastic Syndrome (MDS)
In Brief
A Phase 2 clinical trial evaluating Eltrombopag Olamine, Laboratory Biomarker Analysis, and 1 other intervention for Adult Myelodysplastic Syndrome and 2 related conditions. Completed, enrolled 52 participants across 2 sites.
Detailed Summary
This phase II trial studies how well lenalidomide (LEN) and eltrombopag olamine (ELT) work in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome (MDS). Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given PO